Pfizer Inc. (NYSE:PFE) Shares Bought by RTD Financial Advisors Inc.

RTD Financial Advisors Inc. grew its holdings in shares of Pfizer Inc. (NYSE:PFE) by 1.2% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 52,692 shares of the biopharmaceutical company’s stock after purchasing an additional 636 shares during the period. RTD Financial Advisors Inc.’s holdings in Pfizer were worth $1,335,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the business. Lipe & Dalton increased its holdings in shares of Pfizer by 17.7% during the fourth quarter. Lipe & Dalton now owns 2,659 shares of the biopharmaceutical company’s stock valued at $71,000 after purchasing an additional 400 shares during the period. Beam Wealth Advisors Inc. increased its holdings in shares of Pfizer by 1.5% during the fourth quarter. Beam Wealth Advisors Inc. now owns 27,444 shares of the biopharmaceutical company’s stock valued at $728,000 after purchasing an additional 401 shares during the period. Providence Capital Advisors LLC boosted its stake in Pfizer by 0.4% during the fourth quarter. Providence Capital Advisors LLC now owns 114,358 shares of the biopharmaceutical company’s stock valued at $3,034,000 after buying an additional 409 shares in the last quarter. Donaldson Capital Management LLC grew its holdings in Pfizer by 1.2% during the fourth quarter. Donaldson Capital Management LLC now owns 35,694 shares of the biopharmaceutical company’s stock worth $947,000 after acquiring an additional 410 shares during the period. Finally, Noesis Capital Mangement Corp grew its holdings in Pfizer by 2.6% during the fourth quarter. Noesis Capital Mangement Corp now owns 16,357 shares of the biopharmaceutical company’s stock worth $434,000 after acquiring an additional 413 shares during the period. 68.36% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on PFE. UBS Group lifted their target price on Pfizer from $24.00 to $25.00 and gave the stock a “neutral” rating in a report on Wednesday, April 30th. Guggenheim reaffirmed a “buy” rating on shares of Pfizer in a report on Tuesday, March 18th. Citigroup reaffirmed a “neutral” rating on shares of Pfizer in a report on Thursday, March 27th. Hsbc Global Res raised Pfizer to a “strong-buy” rating in a report on Monday, March 10th. Finally, Cantor Fitzgerald started coverage on Pfizer in a research report on Tuesday, April 22nd. They issued a “neutral” rating and a $24.00 price target for the company. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, four have given a buy rating and three have given a strong buy rating to the company. According to MarketBeat.com, Pfizer currently has a consensus rating of “Moderate Buy” and a consensus target price of $29.17.

Pfizer Trading Down 1.3%

Shares of NYSE PFE opened at $24.51 on Friday. Pfizer Inc. has a one year low of $20.92 and a one year high of $31.54. The firm has a market capitalization of $139.35 billion, a PE ratio of 17.38, a PEG ratio of 0.64 and a beta of 0.57. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The business has a 50-day moving average price of $23.06 and a two-hundred day moving average price of $24.96.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.67 by $0.25. The business had revenue of $13.72 billion during the quarter, compared to analyst estimates of $14.43 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm’s revenue was down 7.8% on a year-over-year basis. During the same period in the previous year, the company earned $0.82 EPS. As a group, analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, June 13th. Stockholders of record on Friday, May 9th were issued a dividend of $0.43 per share. The ex-dividend date was Friday, May 9th. This represents a $1.72 annualized dividend and a dividend yield of 7.02%. Pfizer’s dividend payout ratio is 124.64%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.